Bestatin : Aminopeptide inhibitor

Randomized Double-blind Placebo-controlled Trial of Bestatin in Patients with Resected Stage I Squamous Cell Lung Carcinoma (PubMed)
Summary of a trial reported in the April 16th issue of the Journal of the National Cancer Institute to determine whether post-operative adjuvant treatment with bestatin could prolong the survival of patients with completely resected State I squamous cell lung carcinoma. Study concluded that survival was statistically better for patients who were treated with bestatin postoperatively than for those who received a placebo. Recommends that results be confirmed in other Phase III trials. [4/03]

Bestatin - Recent MEDLINE Abstracts